Inamed Performance Enhanced By Tech Assessment: Shares Up 38% In May
This article was originally published in The Gray Sheet
Executive Summary
Positive safety results from an NIH-sponsored, retrospective study of silicon gel breast implants triggered a $14.25 leap in Inamed shares for the month of May
You may also be interested in...
Silicone Breast Implant Data Requirements Questioned By Patient Groups
FDA's General & Plastic Surgery Devices Panel will likely consider gel migration and "silent rupture" of silicone breast implants when reviewing Inamed's premarket application
Silicone Breast Implant Data Requirements Questioned By Patient Groups
FDA's General & Plastic Surgery Devices Panel will likely consider gel migration and "silent rupture" of silicone breast implants when reviewing Inamed's premarket application
NCI Silicone Breast Implant Study Will Assess Connective Tissue Disease
Follow-up analyses of a 13,500-patient silicone breast implant study will evaluate the relationship of the devices to connective tissue diseases (CTD), according to a 1report submitted to Congress by the National Institutes of Health April 24